Major win in the fight against pancreatic cancer

Researchers recently announced the results of a major European trial at the American society of Clinical Oncology (ASCO) the ESPAC-4 Trial.

In this study patients who had their pancreatic cancer surgically removed had either the traditional Gemcitabine chemotherapy or Gemcitabine with the addition of capecitabine.

This did not result in significant increased toxic effects but resulted in improved survival.

Patients assigned the chemotherapy combination achieved longer median Overall survival (28 months vs. 25.5 months; HR = 0.82; 95% CI, 0.68-0.98) and were more likely to survive 5 years (29% vs. 16%).

This represents a major advance in pancreatic cancer treatment and is likely to become the standard of care for patients in Australia.

Unfortunately only a small number of patients with pancreatic cancer ever come to surgery and we still have to work hard at finding ways to increase survival in those not able to have surgery due to cancer spread or local extent or general medical fitness.

Review by Dr Mehrdad Nikfarjam.

Read the original article here.